Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK120 in Moderate to Severe Atopic Dermatitis
NCT06092762Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of manfidokimab in atopic dermatitis (AD) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Incidence of adverse events. Started Nov 2023; status: completed.
02
Drugs
manfidokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06092762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092762.